Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation

Major Program(s) or Research Group(s)

  • Gastrointestinal and Other Cancers
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02521285

This randomized phase II trial studies the safety of and how well aspirin works in preventing
Barrett's esophagus from returning after it has been successfully eliminated by
radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus
for the levels of a specific protein that is linked to developing Barrett's esophagus may
help doctors learn whether aspirin can prevent it from returning after it has been
successfully treated.

Intervention

Aspirin, Laboratory Biomarker Analysis, Questionnaire Administration, Placebo Administration

Condition

Barrett Esophagus

Investigators

Robert S Bresalier

See list of participating sites